GlassScriptPhysician profile
Mary A Poag
NPI 1275595969
$4,845.78
in general payments reported to CMS, 2019-2025
31 companies · $879 in 2025
The $879 reported for 2025 was more than what 82% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $140 · 2021: $185 · 2022: $712 · 2023: $1,030 · 2024: $1,142 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,037.85 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $497.19 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $455.94 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $451.36 | 2022-2025 | |
| Amgen INC. | $375.76 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $325.92 | 2019-2023 | |
| Millicent US INC | $290.59 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $287.51 | 2019-2025 | |
| Hologic Sales and Service, LLC | $278.21 | 2019-2024 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Biogen, INC. | $254.13 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $204.59 | 2021-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $167.78 | 2019-2025 | Slynd, Nuvessa |
| Sumitomo Pharma America, INC. | $157.40 | 2023-2024 | Myfembree |
| Exact Sciences Corporation | $127.10 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $118.08 | 2022-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $115.60 | 2023 | Myrisk |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.95 | 2019-2022 | |
| Coopersurgical, INC. | $84.04 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $80.58 | 2019-2020 | |
| Agile Therapeutics, INC. | $66.40 | 2023-2024 | Twirla |
| Lupin INC. | $53.27 | 2019-2020 | |
| Radius Health, INC. | $46.06 | 2019-2020 | |
| Shield Therapeutics INC | $45.24 | 2025 | |
| Ascend Therapeutics US, LLC | $44.20 | 2023-2024 | |
| Covidien LP | $42.79 | 2019-2020 | |
| Duchesnay USA Incorporated | $41.61 | 2019 | |
| Myovant Sciences INC. | $36.13 | 2022 | |
| Avion Pharmaceuticals | $30.13 | 2019-2021 | |
| Therapeuticsmd, INC. | $18.85 | 2019 | |
| Lilly USA, LLC | $18.54 | 2025 | Zepbound, Mounjaro |
| Ferring Pharmaceuticals INC. | $17.30 | 2019 | |
| Aspira Women'S Health INC | $16.53 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Poag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.